Medi-Tate Overview
Medi-Tate develops new solutions for treating diseases of the urethra and prostate. Its solutions are designed to reduce associated symptoms and significantly improve patients' quality of life. The Medi-Tate device offers patients relief from the symptoms of benign prostate hyperplasia (BPH). The device is placed in the prostatic urethra for five days. During this time, it pushes obstructive tissue to the side, reshaping the prostate to create a long-term therapeutic effect. The device can be deployed in any clinical setting with standard rigid cystoscopy equipment. The deployment procedure is intuitive and does not require a postprocedural catheter. Once the device is deployed, the patient is free to return to normal activities immediately. Medi-Tate's iTind system for the treatment of BPH is CE marked and available for sale in the European Union, Canada, Hong Kong, and Israel. In April 2020, the company received an FDA De Novo classification for its iTind system.
Cumulative Funding Raised Over Time ($)
$8.0MJul 2016
$10.0MMay 2015
$30.0MNov 2018
Latest News
growth-positive
First BPH Treatment Procedures Performed in Canada with Minimally Invasive iTind Device
Olympus has announced the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind procedure. Dr. Dean Elterman, a urologist, performed the procedure, offering a treatment option beyond medication, surgery, or permanent implants. BPH affects a significant percentage of men, and the iTind procedure provides quick and effective relief from symptoms. The procedure takes a week and involves reshaping the prostate using a temporary implant. Most men can go home without the need for a catheter after the device is removed. The iTind procedure can be offered by physicians in various settings, including smaller, rural facilities. Olympus is a leading medical technology company focused on creating customer-driven solutions for the medical industry.
Customers
growth-positive
Study Results Show Long-term Efficacy of iTind Procedure
Olympus announced the summary results of a follow-up study on the durability of the iTind procedure for treating lower urinary tract symptoms caused by BPH. The study showed long-term efficacy and durability of up to 6.6 years. Two out of 50 patients required subsequent surgical intervention, but no complications were reported. The results demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms. The study results were highly anticipated by urologists and generated high interest in the iTind device at the American Urological Association Annual Meeting.
Customers
growth-positive
Olympus Selected To Exhibit iTind Device For BPH Treatment At Vizient Innovative Technology Exchange
Olympus will exhibit its iTind device for relief of enlarged prostate symptoms at the Vizient Innovative Technology Exchange. The device offers a minimally invasive treatment option that rapidly relieves symptoms while preserving sexual function. The annual exchange allows suppliers to demonstrate their technologies to supply chain and clinical leaders from Vizients member hospitals. The iTind device reshapes the prostate using temporary implants, creating channels for urine flow. It avoids complications associated with drugs, surgery, or permanent implants. Olympus aims to improve clinical outcomes, reduce costs, and enhance patients quality of life. The company is excited to showcase the positive outcomes of the iTind device at the exchange.
PartnersCustomers
growth-positive
Olympus buys Israeli co Medi-Tate for $300m
Japanese medical device company Olympus Corp. is acquiring Israeli medical device company Medi-Tate at a company valuation of $300 million. Medi-Tate develops minimally-invasive treatments for the lower urinary tract. The acquisition represents a profitable exit for Medi-Tates shareholders, including Olympus. Following the acquisition, Medi-Tate will become Olympus R&D Center in Israel. Olympus is traded on the Tokyo Stock Exchange with a market cap of $27 billion. Cooperation between Olympus and Medi-Tate began in 2018 when Olympus received distribution rights to Medi-Tates products. Medi-Tates flagship product is iTind, a device for treating benign prostate hyperplasia. BPH affects almost 50% of men over 50 and is a common reason for lower urinary tract symptoms. The cost of treating BPH in the US is estimated at $10 billion per year.
Acquisition
growth-positive
iTind for Benign Prostatic Hyperplasia Gets FDA Green Light - TMG Pulse
Medi-Tates iTind System, a temporary implantable nitinol device for the relief of lower urinary tract symptoms, has received investment from Olympus, who also has the option to purchase the company. The iTind System offers rapid symptom relief, preserves sexual function, and is a straightforward and easy ambulatory procedure. It does not require a permanent implant or a catheter, and has minimal downtime. The FDA has also provided related study results for the device. The article does not mention any specific customers, acquisition or investment amounts, or layoffs. The date of the event described in the article is not provided.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30M |
| Last funding | $20M |
| Stage | Acquired |
| Rounds | 3 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.itind.com/ |
Photos & Videos
3 item(s)
Medi-Tate Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Materials & SubstancesImplantsTags (11)
non-surgicalminimally-invasivetherapeutic-devicesendoscopyurinary-systemurologymedical-devicespatientshospitalsclinicstreatmentsGeographic Markets
CanadaIsraelEuropeHong KongMedi-Tate Financials
$30M
Total funding
Undisclosed
Capital raised
$20M
Last funding
Acquired
Funding stage
3
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$8.0MJul 2016
$10.0MMay 2015
$30.0MNov 2018
Private Equity Funding
Undisclosed Round
Nov 2018
$20M
Olympus Corporation
B Round
Jul 2016
$8M
Laborie Medical Technologies, Xenia Venture Capital
A Round
May 2015
$2M
Xenia Venture Capital
Public Offering / Exit
MNAEvent
Feb 2021
$250M
Medi-Tate Lifecycle
Cumulative Funding Raised Over Time
$8.0MJul 2016
$10.0MMay 2015
$30.0MNov 2018
All Events
Undisclosed Round
Nov 2018
$20M
Olympus Corporation
B Round
Jul 2016
$8M
Laborie Medical Technologies, Xenia Venture Capital
A Round
May 2015
$2M
Xenia Venture Capital
MNAEvent
Feb 2021
$250M
Medi-Tate News
13 articles
growth-positive
First BPH Treatment Procedures Performed in Canada with Minimally Invasive iTind Device
Olympus has announced the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind procedure. Dr. Dean Elterman, a urologist, performed the procedure, offering a treatment option beyond medication, surgery, or permanent implants. BPH affects a significant percentage of men, and the iTind procedure provides quick and effective relief from symptoms. The procedure takes a week and involves reshaping the prostate using a temporary implant. Most men can go home without the need for a catheter after the device is removed. The iTind procedure can be offered by physicians in various settings, including smaller, rural facilities. Olympus is a leading medical technology company focused on creating customer-driven solutions for the medical industry.
Customers
growth-positive
Study Results Show Long-term Efficacy of iTind Procedure
Olympus announced the summary results of a follow-up study on the durability of the iTind procedure for treating lower urinary tract symptoms caused by BPH. The study showed long-term efficacy and durability of up to 6.6 years. Two out of 50 patients required subsequent surgical intervention, but no complications were reported. The results demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms. The study results were highly anticipated by urologists and generated high interest in the iTind device at the American Urological Association Annual Meeting.
Customers
growth-positive
Olympus Selected To Exhibit iTind Device For BPH Treatment At Vizient Innovative Technology Exchange
Olympus will exhibit its iTind device for relief of enlarged prostate symptoms at the Vizient Innovative Technology Exchange. The device offers a minimally invasive treatment option that rapidly relieves symptoms while preserving sexual function. The annual exchange allows suppliers to demonstrate their technologies to supply chain and clinical leaders from Vizients member hospitals. The iTind device reshapes the prostate using temporary implants, creating channels for urine flow. It avoids complications associated with drugs, surgery, or permanent implants. Olympus aims to improve clinical outcomes, reduce costs, and enhance patients quality of life. The company is excited to showcase the positive outcomes of the iTind device at the exchange.
PartnersCustomers
growth-positive
Olympus buys Israeli co Medi-Tate for $300m
Japanese medical device company Olympus Corp. is acquiring Israeli medical device company Medi-Tate at a company valuation of $300 million. Medi-Tate develops minimally-invasive treatments for the lower urinary tract. The acquisition represents a profitable exit for Medi-Tates shareholders, including Olympus. Following the acquisition, Medi-Tate will become Olympus R&D Center in Israel. Olympus is traded on the Tokyo Stock Exchange with a market cap of $27 billion. Cooperation between Olympus and Medi-Tate began in 2018 when Olympus received distribution rights to Medi-Tates products. Medi-Tates flagship product is iTind, a device for treating benign prostate hyperplasia. BPH affects almost 50% of men over 50 and is a common reason for lower urinary tract symptoms. The cost of treating BPH in the US is estimated at $10 billion per year.
Acquisition
growth-positive
iTind for Benign Prostatic Hyperplasia Gets FDA Green Light - TMG Pulse
Medi-Tates iTind System, a temporary implantable nitinol device for the relief of lower urinary tract symptoms, has received investment from Olympus, who also has the option to purchase the company. The iTind System offers rapid symptom relief, preserves sexual function, and is a straightforward and easy ambulatory procedure. It does not require a permanent implant or a catheter, and has minimal downtime. The FDA has also provided related study results for the device. The article does not mention any specific customers, acquisition or investment amounts, or layoffs. The date of the event described in the article is not provided.
InvestmentPartners
growth-positive
Medi-tate raises $20m from Japanese co Olympus
Medi-tate, a medical devices company, has raised $20 million from Japanese medical devices company Olympus. The investment has resulted in a 28% increase in the share price of Xenia Venture Capital, which holds 14% of Medi-tate. The product developed by Medi-tate for the treatment of benign prostate tumors has been approved for marketing in Europe. Under the agreement, Olympus has obtained distribution rights in Japan and an option to acquire Medi-tate. Xenia reported that its assets would increase by NIS 5 million and potentially by NIS 90 million more if Olympus were to acquire Medi-tate. The controlling shareholder in Xenia is Centaurus Investments, owned by UK businessperson Vincent Tchenguiz.
InvestmentAcquisition
growth-positive
Medi-Tate Ltd., Announces the Enrollment of the First Fifty Patients in its Second Multi-center European Study on iTind
Medi-Tate Ltd. has announced the enrollment of the first fifty patients in its second multi-center European study on the iTind, a minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The study aims to demonstrate the safety and effectiveness of the iTind System in patients of all ages with prostate volumes of up to 120ml. The company hopes to expand the use of iTind to a greater number of men, including those with prostates larger than 75ml. The iTind System is a CE Marked technology available in Europe, Canada, and Hong Kong. Medi-Tate is an Israeli medical device company focused on developing solutions for the treatment of Lower Urinary Tract Symptoms (LUTS) caused by BPH.
Customers
growth-positive
Medi-Tate's Minimally Invasive TIND System for Enlarged Prostate Now Shown to be Durable Through Three Years: Results From Pilot Study
Medi-Tate Ltd., a medical device company, announced the publication of three-year follow-up data from a pilot feasibility study. The study evaluated the safety and effectiveness of the companys prototype for the novel iTind System, developed as a treatment for patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The results showed that the iTind procedure is safe, effective, and well-tolerated for at least 36 months. The studys authors noted that the iTind System offers a minimally invasive alternative for treating BPH symptoms while preserving sexual function. The company is encouraged by the results and excited about the growing clinical adoption of the procedure.
Customers
growth-positive
The tiny cage that cuts the number of times men need the loo
A tiny wire cage implant called iTIND has shown promising results in improving urine flow for men suffering from an enlarged prostate. The implant, which is removed after five days, allows patients to stop taking medication immediately and most were symptom-free three years later. The standard treatment for an enlarged prostate includes medication and surgical options, but these can have side effects. The iTIND treatment, made from a metal called nitinol, is inserted through the urethra and expands to its normal size, widening the urethra and providing relief. A study of 32 patients showed significant improvement in urine flow and no sexual dysfunction or incontinence as a result of the treatment. Other treatments for an enlarged prostate, such as steam therapy, are also being explored.
Customers
growth-positive
Laborie Completes Strategic Investment In Medi-Tate Ltd.
Laborie Medical Technologies has completed an investment in Medi-Tate Ltd., an Israeli medical device company focused on the treatment of Benign Prostatic Hyperplasia (BPH). Medi-Tate has developed iTind, a minimally invasive procedure for treating enlarged prostate. LABORIEs investment in Medi-Tate aligns with their focus on providing innovative products for Urology and Gastroenterology customers. The partnership will allow the companies to bring the iTind solution to the market more quickly and benefit the over 500 million aging men impacted by BPH. LABORIE is a leading global developer, manufacturer, and marketer of medical technology and consumables for Urodynamics and Gastroenterology.
Investment
growth-positive
Prostate tumor device co Medi-Tate raises $8m
Medi-Tate, an Israeli medical devices company, has raised $4 million in a financing round from a strategic investor. The companys value is now $50 million. The investor has the option to acquire the entire company at a value of $100-200 million. The acquisition value will depend on the stage of Medi-Tate at the time of acquisition. The company has also secured the right to receive an additional $2 million investment from another investor. The financing round will enable Medi-Tate to progress in regulatory matters and collaborate with international medical devices players.
InvestmentAcquisition
growth-positive
Medical device co Medi-tate raises $2m
Xenia Venture Capital Ltd. has completed a $2 billion financing round for Medi-tate, a portfolio company specializing in the development of products for the treatment of urethra and prostate diseases. Medi-tates flagship product, iTIND 555, has received CE certification for marketing in Europe and is aimed at a potential market of $1 billion. The product offers a simple and minimally invasive procedure for treating benign prostate hyperplasia (BPH). In addition to the European market, there are 15 million BPH sufferers in the US, with a market estimated at $3 billion. The financing round is expected to contribute to the growth of Medi-tate and its innovative medical device.
Investment
growth-positive
Medi-tate wins EU CE Mark for prostrate device
Medi-tate Ltd. has obtained EU CE Mark certification for its mechanical Benign Prostate Hyperplasia (BPH) device. The device offers a unique solution to patients and urologists, achieving surgery-like results using a minimally invasive office procedure. The company aims to tap into the $3 billion US BPH market. Medi-tate is a portfolio company of Xenia Venture Capital Ltd.
CustomersInvestment
Medi-Tate Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Medi-Tate Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 87/100 |
| Missing | address, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513946632 |
| Crunchbase | medi-tate |
| Phone | +972777006745 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-10-18T00:00:00.000Z |
| Created | 2015-01-01T00:00:00.000Z |
| Status detail | Acquired by Olympus Corporation on Feb, 2021 |